Insider buying last 90 days
No open-market insider purchases were filed for ELVN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ELVN insider filing, plotted on the chart in Gekko.Open ELVN in Gekko
NASDAQ: ELVN
Enliven Therapeutics (ELVN) Stock Analysis & Forecast
Oct 12 close
$40.84−0.14 (−0.3%)
Gekko Brief
AI summaryOct 12 closeEnliven Therapeutics this week drew attention mainly for FDA alignment on the ENABLE-2 pivotal Phase 3 trial design for relcobatinib (ELVN-001) in previously treated chronic myeloid leukemia, a regulatory milestone reported across multiple items on 7 October. Separately, shares fell 4.5% on 6 October following insider selling, with director Scott Garland reported to have sold $606,000 in stock after exercising options; a Form 4 filing on 12 October also registered.
ELVN closed at $40.84, down 0.3%, sitting between its 50-day average of $53.71 and 200-day average of $41.17, with one-month and three-month returns of -24.8% and -21.1% against a one-year return of 91.8%. The GekkoIndex reads 69.3, placing the stock in the Accumulation zone, up 2.5 over five days. Price sits 27.7% below Gekko Fair Value of $56.48.
The next earnings date is 11 November, 29 days out and beyond a typical 20-trading-day hold, with the last report showing an EPS miss of -0.48 versus -0.38 estimated and a -9.5% reaction; six of the last eight quarters beat estimates, with an average absolute reaction of 4.3%. No insider, Congress or unusual options activity appears within their respective 90-day and 30-day windows. Seasonality over the past 5 years shows an average 20-day return of 14.2% from this point, though gains occurred in only 2 of those years. Analyst coverage from 13 firms is unanimously rated buy, with a consensus target of $73.67.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Enliven Therapeutics price vs fair value
Close $40.84200-day averageGekko Fair Value $56.48
Enliven Therapeutics quick facts
- Market cap
- $2.92B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.67
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.34
- Volume
- 579,822 avg 1.59M
- 1-year return
- +91.8%
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±11.3%
- 50-day average
- $53.71
- 200-day average
- $41.17
- Next earnings
- Nov 11
- Shares outstanding
- 73.27M
Enliven Therapeutics swing-trade checklist
Enliven Therapeutics scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $40.84 sits between the 50-day ($53.71) and 200-day ($41.17) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
69.3, Accumulation
Reading 69.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
27.7% below
Price is 27.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+14.2% on average
From this point in the calendar, the next 20 trading days averaged +14.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Enliven Therapeutics stock chart and price history
Enliven Therapeutics closed at $40.84 on Oct 12, 2026, +91.8% over the past year, inside a 52-week range of $14.79 to $62.32.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −24.8%
- 3 months
- −21.1%
- 6 months
- −6.8%
- 1 year
- +91.8%
The full ELVN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ELVN in Gekko
Follow Enliven Therapeutics through every session
Put ELVN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ELVN in GekkoFree for 7 days. No credit card required.
About Enliven Therapeutics
Enliven Therapeutics works in clinical-stage biopharmaceutical research, focused on finding and developing small molecule drugs to treat cancer. Among its programs is ELVN-001, a kinase inhibitor being tested in a Phase 1 trial for adults with chronic myeloid leukemia. A second candidate, ELVN-002, is also a kinase inhibitor and has entered Phase 1 testing for cancers linked to an abnormal HER2 gene.
The company centers its activity on advancing these drug candidates through clinical trials rather than selling commercial products, with its work directed at patients affected by these specific cancer types.
Enliven Therapeutics is based in Boulder, Colorado. Its shares are listed on the NASDAQ under the ticker ELVN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- enliventherapeutics.com
Enliven Therapeutics GekkoIndex: the smart money zone
Enliven Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.3, in the Accumulation zone, up 2.5 points over five sessions.
69.3Accumulation
Up 2.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | Not available | |||
| Accumulation (current zone) | 188 | +2.1% | +10.2% | ||
| Neutral | 422 | +0.5% | +1.4% | ||
| Distribution | 36 | +0.1% | +0.8% | ||
| Selling | 9 | Too few readings yet | |||
Average ELVN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ELVN price, zone by zone.Track ELVN in Gekko
Is Enliven Therapeutics stock overvalued? Gekko Fair Value
Enliven Therapeutics trades 27.7% below Gekko Fair Value of $56.48, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Enliven Therapeutics shares are worth, recalculated every trading day.
$56.48
Gekko Fair Value, Oct 10, 2026
27.7% Undervalued
At the end of Aug 2026 the price was 13.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ELVN in Gekko
Enliven Therapeutics insider and Congress trading
No open-market insider purchases were filed for Enliven Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ELVN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ELVN, plotted on the chart in Gekko.Open ELVN in Gekko
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold ELVN.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Enliven Therapeutics earnings: next date and track record
Enliven Therapeutics reports on Nov 11, 2026 (30 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 11, 2026
30 days away
- EPS estimate
- −$0.48
6 of 8reports beat the EPS estimate
±4.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 12, 2026 | −$0.48 est −$0.38 | — | −9.5% |
| Nov 12, 2025 | −$0.32 est −$0.43 | — est $8K | +3.2% |
| Aug 13, 2025 | −$0.49 est −$0.53 | — | +4.7% |
| May 12, 2025 | −$0.57 est −$0.50 | — | +8.7% |
| Mar 12, 2025 | −$0.46 est −$0.52 | — | −1.9% |
| Nov 7, 2024 | −$0.48 est −$0.50 | — | −2.0% |
| Aug 13, 2024 | −$0.41 est −$0.55 | — | +2.3% |
| May 14, 2024 | −$0.54 est −$0.57 | — | −2.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Enliven Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Enliven Therapeutics is $73.67, +80.4% from the last close, from 13 firms rating the stock in the last 90 days.
$73.67consensus 12-month target, +80.4% from the last close
Now $40.84Avg $73.67
Low $68High $82
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Barclays | $78 | +91.0% |
| Oct 7 | TD Cowen | — | — |
| Oct 6 | William Blair | — | — |
| Oct 5 | Morgan Stanley | $70 | +71.4% |
| Oct 2 | Morgan Stanley | $70 | +71.4% |
+10.2%average 20-day move after past Accumulation readings
+14.2%average move over the next 20 trading days in the last 5 years
±4.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Enliven Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Enliven Therapeutics averaged +14.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +9.6% | 2 of 5 |
| Next 10 trading days | +17.2% | 2 of 5 |
| Next 15 trading days | +19.4% | 3 of 5 |
| Next 20 trading days | +14.2% | 2 of 5 |
| Next 30 trading days | +9.9% | 2 of 5 |
For scale, ELVN’s typical 20-trading-day move in either direction is about 11.3%.
Enliven Therapeutics market cap and key statistics
Enliven Therapeutics’s market cap is $2.92B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $2.92B
- EPS, TTM
- −$1.67
- Gekko Fair Value
- $56.48
Trading
- Volume
- 579,822
- Avg volume, 20 days
- 1.59M
- 52-week high
- $62.32
- 52-week low
- $14.79
- Shares outstanding
- 73.27M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -15.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.34
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±11.3%
Enliven Therapeutics stock news this week
Coverage of Enliven Therapeutics this week reads positive: 6 positive, 3 neutral and 2 negative headlines.
- Form 4 Enliven Therapeutics Inc For: 12 October By Investing.comInvesting.com India, Oct 12
- Enliven Therapeutics director Scott Garland sells $606k in stock By Investing.comInvesting.com Canada, Oct 12
- The Technical Signals Behind (ELVN) That Institutions FollowStock Traders Daily, Oct 11
- Enliven Therapeutics Announces FDA Alignment On ENABLE-2 Pivotal Phase 3 Trial Design For Relcobatinib In Previously Treated Chronic Myeloid Leukemiawww.marketscreener.com, Oct 7
- Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 TrialYahoo Finance, Oct 7
- Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid LeukemiaPR Newswire, Oct 7
Enliven Therapeutics peers
Enliven Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Enliven Therapeutics stock FAQ
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $2.92B at the Oct 12, 2026 close of $40.84, with 73.27M shares outstanding.
What is the Enliven Therapeutics stock forecast?
The consensus analyst 12-month price target for Enliven Therapeutics is $73.67, +80.4% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Enliven Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Enliven Therapeutics is undervalued: the Oct 12, 2026 close of $40.84 is 27.7% below Gekko Fair Value of $56.48. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Enliven Therapeutics report earnings next?
Enliven Therapeutics is expected to report on Nov 11, 2026 (30 days away). Analysts expect earnings of −$0.48 per share. Enliven Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 4.3% on average across the report.
What is Enliven Therapeutics’s 52-week high and low?
Enliven Therapeutics’s 52-week high is $62.32 and its 52-week low is $14.79; it closed at $40.84 on Oct 12, 2026, +91.8% over the past year.
Is Enliven Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Enliven Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.